IBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc.
06 Julho 2023 - 9:17AM
via IBN – IBN, a multifaceted communications organization engaged
in connecting public companies to the investment community, is
pleased to announce the release of the latest episode of The
Bell2Bell Podcast as part of its sustained effort to provide
specialized content distribution via widespread syndication
channels.
The Bell2Bell Podcast delivers informative updates and exclusive
interviews with executives operating in fast-moving industries.
Bell2Bell’s latest podcast features Chairman, President and CEO
Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX),
a clinical-stage gene therapy company focused on developing
life-changing therapies for patients living with cancer and
diabetes.
In this interview, Varner and Confer discuss the journeys that
led them to Genprex and the promise of the company’s drug
development pipeline.
“This work has become a real passion for me. We have the
opportunity to do real good here at Genprex on a major scale –
helping millions of people around the world with serious diseases
through our novel gene therapies,” said Varner.
Confer then provided some background on what led him to join
Genprex in its early days and remain with the company for well over
a decade.
“As I learned more and more about the technology, it became a
passion of mine, as well,” said Confer. “What we’re trying to do in
cancer – using a lipid-based delivery vehicle and working with
tumor suppressor genes that are naturally occurring in the body –
represents a treatment paradigm that is unique and different than
other options in the space, particularly chemotherapy that has such
negative side effects. It is something that we believe really has
the potential to change people’s lives as they’re going through
such a terrible prognosis. I was excited then, and here we are 12
years later, being able to see it coming through clinical trials,
seeing how safe the program has been and seeing the impact that
we’re having.”
Varner and Confer also discuss the company’s cancer and diabetes
treatments in greater detail.
“Our cancer treatment is distinguished from most other oncology
gene therapies in that we’re using a tumor suppressor gene that is
delivered to the tumor by a non-viral lipid nanoparticle,” said
Varner. “The nanoparticles deliver the therapeutic DNA into the
tumor, where our drug candidate does a number of things to reduce
or eliminate the tumor.”
“We also have a really unique pre-clinical diabetes program.
Unlike our oncology program, we use a viral delivery system with
our diabetes program. However, we have a process in which we
deliver genes directly to the pancreas using an endoscopic
procedure to be able to localize the viral vector in that specific
organ,” explained Confer.
Join IBN’s Stuart Smith and Chairman, President and CEO Rodney
Varner and CFO Ryan Confer of Genprex Inc. (NASDAQ: GNPX), to learn
more about the promise of gene therapy and Genprex’s development
pipelines targeting oncology and diabetes.
To hear the episode and subscribe for future podcasts,
visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to
reinforce IBN’s commitment to the expansion of its robust network
of brands, client partners, followers, and the growing IBN Podcast
Series. For more than 17 years, IBN has leveraged this commitment
to provide unparalleled distribution and corporate messaging
solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a
visual timeline, visit: https://IBN.fm/TimeLine
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused
on developing life-changing therapies for patients living with
cancer and diabetes. The company’s technologies are designed to
administer disease-fighting genes to provide new therapies for
large patient populations who currently have limited treatment
options.
Genprex works with world-class institutions and collaborators to
develop drug candidates to further its pipeline of gene therapies
in order to provide novel treatment approaches. The company was
founded in 2009 and is headquartered in Austin, Texas.
For more information, visit the company’s website at
www.Genprex.com.
About IBN
IBN consists of financial brands introduced to the investment
public over the course of 17+ years. With IBN, we have amassed a
collective audience of millions of social media followers. These
distinctive investor brands aim to fulfill the unique needs of a
growing base of client-partners. IBN will continue to expand our
branded network of highly influential properties, leveraging the
knowledge and energy of specialized teams of experts to serve our
increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1)
access to a network of wire solutions via InvestorWire to reach all
target markets, industries and demographics in the most effective
manner possible; (2) article and editorial syndication to 5,000+
news outlets; (3) Press Release Enhancement to ensure maximum
impact; (4) full-scale distribution to a growing social media
audience; (5) a full array of corporate communications solutions;
and (6) total news coverage solutions.
For more information, please visit
https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBNLos Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Genprex (NASDAQ:GNPX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Genprex (NASDAQ:GNPX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024